Plain-English translation of NCT06452732 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is looking for a better way to predict whether children with acute myeloid leukemia will relapse (have their cancer return) after chemotherapy. Researchers will use an advanced blood test called multiparametric flow cytometry to find cancer stem cells that may remain in the blood even after treatment. By catching these cells early, doctors hope to give additional treatment before the cancer comes back.
Current tests for predicting relapse are not accurate enough — they miss some cases and give false alarms in others. This study exists because finding a more reliable way to predict which children will relapse could help doctors start preventive treatment sooner and save more lives.
You likely qualify if…
You likely don't qualify if…
As a participant, you would have blood and bone marrow samples taken regularly during and after your leukemia treatment. These samples will be tested using a special technique to look for remaining cancer cells that might signal a higher risk of relapse. The study will follow you over time to see if the test accurately predicts which children have better or worse outcomes.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Peking University People's Hospital
Collaborators
The First Affiliated Hospital of Zhengzhou University
Enrollment target
~283 participants
Started
November 2024
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yingjun Chang Y Prof. Ying-Jun Chang Chang
Peking University People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.